THeragnostic utilities for neoplastic DisEases of the rectum by MRI guided radiotherapy (THUNDER 2) phase II trial: interim safety analysis.
Chemoradiotherapy
Dose escalation
Early Regression Index
Magnetic resonance guided Radiation Therapy
Radiomics
Rectal cancer
Watch and wait
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
received:
17
07
2023
accepted:
19
09
2023
medline:
1
11
2023
pubmed:
7
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
The THUNDER-2 phase II single institutional trial investigates the benefits of MRI-guided radiotherapy (MRIgRT) in treating locally advanced rectal cancer (LARC). This study focuses on evaluating the impact of escalating radiation therapy dose in non-responder patients using the Early Tumour Regression Index (ERI) for predicting complete response (CR). The trial's primary endpoint is to increase the CR rate in non-responders by 10% and assess the feasibility of the delta radiomics-based MRIgRT predictive model. This interim analysis assesses the feasibility and safety of the proposed MRIgRT dose escalation strategy in terms of acute toxicity (gastrointestinal, genitourinary and haematological) and treatment adherence. Stage cT2-3, N0-2, or cT4 patients with anal sphincter involvement, N0-2a, M0, but without high-risk features were enrolled. MRIgRT treatment consisted of a standard dose of 55 Gy to the Gross Tumor Volume (GTV) and mesorectum, and 45 Gy to the mesorectum and drainage nodes in 25 fractions with concomitant chemotherapy. 0.35 T MRI was used for simulation imaging and daily alignment. ERI was calculated at the 10th fraction. Non-responders with an ERI above 13.1 received intensified dose escalation from the 11th fraction, resulting in a total dose of 60.1 Gy. Acute toxicity was assessed using the CTCAE v.5 scale. From March 2021 to November 2022, 33 out of the total number of 63 patients to be enrolled (52.4%) were included, with one withdrawal unrelated to treatment. Sixteen patients (50%) underwent dose escalation. Treatment was well tolerated, with only one patient (3.1%) in the standard treatment group experiencing acute Grade 3 diarrhea, proctitis, and cystitis. No significant differences in toxicity were observed between the two groups (p = 0.5463). MRIgRT treatment with dose escalation up to 60.1 Gy is well tolerated in LARC patients predicted as non-responders by ERI, confirming the feasibility and safety of this approach. The THUNDER-2 trial's primary and secondary endpoints will be fully analyzed when all planned patients will be enrolled.
Sections du résumé
BACKGROUND
BACKGROUND
The THUNDER-2 phase II single institutional trial investigates the benefits of MRI-guided radiotherapy (MRIgRT) in treating locally advanced rectal cancer (LARC). This study focuses on evaluating the impact of escalating radiation therapy dose in non-responder patients using the Early Tumour Regression Index (ERI) for predicting complete response (CR). The trial's primary endpoint is to increase the CR rate in non-responders by 10% and assess the feasibility of the delta radiomics-based MRIgRT predictive model. This interim analysis assesses the feasibility and safety of the proposed MRIgRT dose escalation strategy in terms of acute toxicity (gastrointestinal, genitourinary and haematological) and treatment adherence.
METHODS
METHODS
Stage cT2-3, N0-2, or cT4 patients with anal sphincter involvement, N0-2a, M0, but without high-risk features were enrolled. MRIgRT treatment consisted of a standard dose of 55 Gy to the Gross Tumor Volume (GTV) and mesorectum, and 45 Gy to the mesorectum and drainage nodes in 25 fractions with concomitant chemotherapy. 0.35 T MRI was used for simulation imaging and daily alignment. ERI was calculated at the 10th fraction. Non-responders with an ERI above 13.1 received intensified dose escalation from the 11th fraction, resulting in a total dose of 60.1 Gy. Acute toxicity was assessed using the CTCAE v.5 scale.
RESULTS
RESULTS
From March 2021 to November 2022, 33 out of the total number of 63 patients to be enrolled (52.4%) were included, with one withdrawal unrelated to treatment. Sixteen patients (50%) underwent dose escalation. Treatment was well tolerated, with only one patient (3.1%) in the standard treatment group experiencing acute Grade 3 diarrhea, proctitis, and cystitis. No significant differences in toxicity were observed between the two groups (p = 0.5463).
CONCLUSIONS
CONCLUSIONS
MRIgRT treatment with dose escalation up to 60.1 Gy is well tolerated in LARC patients predicted as non-responders by ERI, confirming the feasibility and safety of this approach. The THUNDER-2 trial's primary and secondary endpoints will be fully analyzed when all planned patients will be enrolled.
Identifiants
pubmed: 37803322
doi: 10.1186/s13014-023-02353-x
pii: 10.1186/s13014-023-02353-x
pmc: PMC10557246
doi:
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
163Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
J Gastrointest Oncol. 2017 Oct;8(5):902-914
pubmed: 29184696
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):323-7
pubmed: 10661338
J Clin Oncol. 2004 Jun 15;22(12):2404-9
pubmed: 15197202
Strahlenther Onkol. 2012 Jan;188(1):97-9
pubmed: 22234506
J Clin Oncol. 2005 Mar 20;23(9):1847-58
pubmed: 15774778
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1347-1356
pubmed: 32758641
Radiat Oncol. 2022 Dec 28;17(1):214
pubmed: 36578032
Radiother Oncol. 2019 May;134:110-118
pubmed: 31005204
Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):99-107
pubmed: 18407433
BMC Cancer. 2022 Jan 15;22(1):67
pubmed: 35033008
World J Clin Cases. 2021 Oct 26;9(30):9077-9089
pubmed: 34786390
Clin Transl Radiat Oncol. 2019 Apr 08;18:66-67
pubmed: 31341978
Clin Transl Radiat Oncol. 2023 Jan 12;39:100579
pubmed: 36935859
Clin Transl Radiat Oncol. 2019 Apr 12;18:80-86
pubmed: 31341981
Sci Rep. 2022 Dec 8;12(1):21263
pubmed: 36481692
Clin Transl Radiat Oncol. 2022 Oct 15;37:153-156
pubmed: 36339638
Radiother Oncol. 2014 Oct;113(1):1-9
pubmed: 25281582
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
Br J Radiol. 2017 Dec;90(1080):20170175
pubmed: 28937269
J Clin Oncol. 2011 Dec 10;29(35):4633-40
pubmed: 22067400
Radiother Oncol. 2018 Sep;128(3):564-568
pubmed: 30196982
Front Oncol. 2021 Mar 30;11:619852
pubmed: 33859937
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):74-80
pubmed: 22763027
Radiother Oncol. 2016 Aug;120(2):195-201
pubmed: 27528121
Ann Surg Oncol. 2011 Dec;18(13):3686-93
pubmed: 21691880
Br J Surg. 2012 Jul;99(7):918-28
pubmed: 22362002
Clin Colorectal Cancer. 2018 Sep;17(3):e499-e512
pubmed: 29678514